FDA approved eltrombopag (Promacta for oral suspension, Novartis) for the treatment of thrombocytopenia in pediatric patients 1 year and older with chronic immune (idiopathic) thrombocytopenia (ITP) who have had an insufficient response to corticosteroids, immunoglobulins, or splenectomy.   August 24, 2015. 

Source: More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm459467.htm

Advertisements